Le Lézard
Classified in: Health
Subjects: NPT, SVY

MASSACHUSETTS RESIDENTS CITE HIGH COSTS AS THE MOST IMPORTANT ISSUE IN HEALTH CARE


Trails only inflation and the cost of housing as top worries

BOSTON, March 20, 2024 /PRNewswire/ -- The cost of care is the most critical health care issue facing Massachusetts residents, according to a new Beacon Research survey commissioned by Blue Cross Blue Shield of Massachusetts ("Blue Cross"). Forty percent of residents surveyed said they are putting off seeing a doctor or going to a hospital due to the cost of care. Further, residents reported noticing the largest health care cost increase from hospital bills.

"These findings underscore what we know and hear from our members on a regular basis," said Sarah Iselin, president and CEO of Blue Cross. "Residents are struggling with health care costs, causing them to put off care and make tough decisions. This is deeply concerning in a state committed to health care access and, without action, could lead to health implications statewide. This poll underscores the urgent need for our health care community to work together on managing costs and ensuring affordable options for residents, businesses, and state government."

Key survey findings included:

"These results show that consumers are deeply concerned about the costs of health care," said Chris Anderson, founder and president of Beacon Research. "This poll provides a real time snapshot of how prices are impacting their decisions on whether to access care and what consumers are experiencing in our health care system statewide."

Blue Cross is working with others in health care to responsibly moderate the growth in health care spending. Among the steps the company is taking:

Methodology

A total of 1,000 Massachusetts adults were interviewed for this survey between February 28- March 6. The survey was conducted using a mixed methodology approach with approximately one-quarter of the interviews conducted by live interviewer telephone calls and three-quarters via a representative online panel. Slight weights were used to bring the demographics of the sample in line with actual demographics of Massachusetts. 

Complete poll results can be found here.

About Blue Cross Blue Shield of Massachusetts
Blue Cross Blue Shield of Massachusetts (bluecrossma.org) is a community-focused, tax-paying, not-for-profit health plan headquartered in Boston. We are committed to showing up for everyone like they're the only one and guiding our members to the exceptional health care they deserve ? affordably, equitably and seamlessly. In keeping with our commitment, we are rated among the nation's best health plans for member satisfaction and quality. Connect with us on FacebookTwitterYouTube, and LinkedIn.

SOURCE Blue Cross Blue Shield of Massachusetts


These press releases may also interest you

at 00:01
America's child care supply remains flat, while child care prices continue to increase, according to a new report released today by Child Care Aware® of America (CCAoA) that highlights the burden families face accessing quality and affordable child...

at 00:01
The cost of living is Gen Zs' and millennials' top societal concern, but green shoots of optimism for the economy and their personal finances are emergingNearly nine in 10 Gen Zs and millennials say purpose is important to their job satisfaction and...

at 00:00
AmacaThera Inc, a clinical stage biotechnology company specializing in the development of advanced sustained release hydrogel formulations, has dosed its first human subject with AMT-143, the company's lead asset in non-opioid acute pain management. ...

14 mai 2024
BioArctic AB's (publ) partner Eisai today said that they expect Leqembi sales to total JPY 56.5 billion (approximately SEK 4 billion) for their fiscal year (FY) 2024 (April 2024 through March 2025). This would generate approximately SEK 360 M in net...

14 mai 2024
The global flow cytometry market  size is estimated to grow by USD 6038.44 million from 2023-2027, according to Technavio. The market is estimated to grow at a CAGR of about 13.12%  during the forecast period....

14 mai 2024
BioArctic AB's (publ) partner Eisai announced today that they have initiated the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for lecanemab-irmb (U.S. brand name: Leqembi) subcutaneous...



News published on and distributed by: